002653 海思科
已收盘 07-17 15:00:00
资讯
新帖
简况
海思科最新公告:获得创新药HSK21542注射液新适应症IND申请《受理通知书》
证券之星 · 07-14
海思科最新公告:获得创新药HSK21542注射液新适应症IND申请《受理通知书》
海思科(002653.SZ)发预增,预计上半年净利润1.5亿元至1.65亿元 增长99.80%-119.78%
智通财经 · 07-11
海思科(002653.SZ)发预增,预计上半年净利润1.5亿元至1.65亿元 增长99.80%-119.78%
海思科最新公告:半年度净利润预增99.8%-119.78%
证券之星 · 07-11
海思科最新公告:半年度净利润预增99.8%-119.78%
海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊新适应症药品注册证书
智通财经网 · 07-07
海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊新适应症药品注册证书
海思科最新公告:创新药苯磺酸克利加巴林胶囊新增适应症获批
证券之星 · 07-07
海思科最新公告:创新药苯磺酸克利加巴林胶囊新增适应症获批
海思科涨5.04%,德邦证券二个月前给出“买入”评级
证券之星 · 07-05
海思科涨5.04%,德邦证券二个月前给出“买入”评级
海思科(002653)6月28日主力资金净卖出621.85万元
证券之星 · 07-01
海思科(002653)6月28日主力资金净卖出621.85万元
海思科:考格列汀片(倍长平®)是全球首个双周口服降糖药,为全球首创,中国首发
证券之星 · 06-26
海思科:考格列汀片(倍长平®)是全球首个双周口服降糖药,为全球首创,中国首发
海思科:获得1类创新药考格列汀片《药品注册证书》
中国财富通 · 06-25
海思科:获得1类创新药考格列汀片《药品注册证书》
海思科(002653.SZ)获得1类创新药考格列汀片药品注册证书
智通财经网 · 06-25
海思科(002653.SZ)获得1类创新药考格列汀片药品注册证书
海思科最新公告:HSK42360片获批临床试验
证券之星 · 06-12
海思科最新公告:HSK42360片获批临床试验
海思科(002653.SZ):创新药HSK42360片获临床试验批准
智通财经 · 06-12
海思科(002653.SZ):创新药HSK42360片获临床试验批准
海思科(002653)5月29日主力资金净买入834.42万元
证券之星 · 05-30
海思科(002653)5月29日主力资金净买入834.42万元
生物医药概念盘中拉升,海思科涨6.11%
自选股智能写手 · 05-29
生物医药概念盘中拉升,海思科涨6.11%
海思科最新公告:获得创新药HSK44459片IND申请的受理通知书
证券之星 · 05-28
海思科最新公告:获得创新药HSK44459片IND申请的受理通知书
海思科(002653.SZ)获得创新药HSK44459片IND申请受理
智通财经网 · 05-28
海思科(002653.SZ)获得创新药HSK44459片IND申请受理
海思科:获得1类创新药苯磺酸克利加巴林胶囊药品注册证书
中国财富通 · 05-21
海思科:获得1类创新药苯磺酸克利加巴林胶囊药品注册证书
海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊《药品注册证书》
智通财经网 · 05-21
海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊《药品注册证书》
海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理
智通财经 · 05-15
海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理
海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书
证券之星 · 05-15
海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书
暂无数据
公司概况
公司名称:
海思科医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-01-17
主营业务:
海思科医药集团股份有限公司的主营业务为医药研发、生产制造、销售。公司的主要产品包括创新药环泊酚注射液、甲磺酸多拉司琼注射液、多烯磷脂酰胆碱注射液、复方氨基酸注射液(18AA-Ⅶ)、氟哌噻吨美利曲辛片、注射用甲泼尼龙琥珀酸钠等。公司获得行业高度认可,连续3年荣获中国创新力医药企业,先后入选2021年度中国化药企业TOP100、2021年福布斯中国最具创新力企业TOP50榜,获评制药行业企业信用等级AAA。公司在“2022-2023年中国医药行业最具影响力榜单”评选中荣膺四项殊荣,分别是医药商业百强企业,医药制造业百强企业,自主创新先锋企业,守法诚信企业。
发行价格:
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":29.7,"timestamp":1721199792000,"preClose":29.95,"halted":0,"volume":2910329,"delay":0,"floatShares":517000000,"shares":1114000000,"eps":0.3217,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.25,"latestTime":"07-17 15:00:00","open":29.75,"high":30.09,"low":29.12,"amount":86106100,"amplitude":0.0324,"askPrice":29.7,"askSize":11,"bidPrice":29.69,"bidSize":5,"shortable":0,"etf":0,"ttmEps":0.3217,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":29.95,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":32.95,"lowLimit":26.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114117970,"pbRate":7.77,"roa":"--","roe":"2.17%","epsLYR":0.27,"committee":-0.530612,"marketValue":33089000000,"floatMarketCap":15357000000,"peRate":92.322037,"changeRate":-0.0083,"turnoverRate":0.0056,"status":1},"requestUrl":"/m/hq/s/002653/tweets","defaultTab":"tweets","newsList":[{"id":"2451686702","title":"海思科最新公告:获得创新药HSK21542注射液新适应症IND申请《受理通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2451686702","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451686702?lang=zh_cn&edition=full","pubTime":"2024-07-14 18:00","pubTimestamp":1720951257,"startTime":"0","endTime":"0","summary":"海思科公告,获得创新药HSK21542注射液新适应症IND申请《受理通知书》。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071400002811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0028","BK1161","159992","BK0188","BK1574","BK0033","002653","BK0239","BK0077"],"gpt_icon":0},{"id":"2450353773","title":"海思科(002653.SZ)发预增,预计上半年净利润1.5亿元至1.65亿元 增长99.80%-119.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450353773","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450353773?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:28","pubTimestamp":1720697305,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)发布2024年半年度业绩预告,预计上半年归属于上市公司股东的净利润1.5亿元至1.65亿元,同比增长99.80%-119.78%。业绩变动原因:1、归属于上市公司股东净利润增长的原因:(1)报告期内公司在环泊酚等产品快速增长的带动下,实现营业收入同比增长约20%。(2)收到政府补助约7,300万元,上年同期无此类事项,非经常性损益受政府补助影响,同比增幅较大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653"],"gpt_icon":0},{"id":"2450353536","title":"海思科最新公告:半年度净利润预增99.8%-119.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450353536","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450353536?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:10","pubTimestamp":1720696227,"startTime":"0","endTime":"0","summary":"海思科公告,预计2024年上半年归属于上市公司股东的净利润1.5亿元–1.65亿元,同比增长99.8%-119.78%。报告期内公司在环泊酚等产品快速增长的带动下,实现营业收入同比增长约20%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100036684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653"],"gpt_icon":0},{"id":"2449375827","title":"海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊新适应症药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449375827","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449375827?lang=zh_cn&edition=full","pubTime":"2024-07-07 15:47","pubTimestamp":1720338474,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)发布公告,公司于2024年7月5日收到国家药品监督管理...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0077","BK1161","BK0188","159992","002653","BK0239","BK1574","06978","BK0033"],"gpt_icon":0},{"id":"2449875849","title":"海思科最新公告:创新药苯磺酸克利加巴林胶囊新增适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2449875849","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449875849?lang=zh_cn&edition=full","pubTime":"2024-07-07 15:39","pubTimestamp":1720337994,"startTime":"0","endTime":"0","summary":"海思科公告,公司于2024年7月5日收到国家药品监督管理局签发的《药品注册证书》,批准公司1类创新药苯磺酸克利加巴林胶囊新增适应症“本品用于治疗成人糖尿病性周围神经病理性疼痛和带状疱疹后神经痛”。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070700001548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0077","159992","BK1161","002653","BK1574","BK0188","BK0028","BK0239","06978"],"gpt_icon":0},{"id":"2449253805","title":"海思科涨5.04%,德邦证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2449253805","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449253805?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:17","pubTimestamp":1720167431,"startTime":"0","endTime":"0","summary":"今日海思科涨5.04%,收盘报31.28元。2024年4月23日,德邦证券研究员李霁阳发布了对海思科的研报《差异化创新布局进入收获期,管线丰富潜力巨大》,该研报对海思科给出“买入”评级。此外,东吴证券研究员朱国广,西南证券研究员杜向阳近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","161027"],"gpt_icon":0},{"id":"2448093314","title":"海思科(002653)6月28日主力资金净卖出621.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448093314","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448093314?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:23","pubTimestamp":1719796998,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月28日收盘,海思科报收于30.7元,下跌2.07%,换手率0.68%,成交量3.51万手,成交额1.09亿元。海思科主营业务:公司是一家集医药研发、生产制造、销售等业务于一体的多元化、专业化医药集团上市公司,公司秉承“以奋斗之心、与生命同行”之理念,始终以客户需求为导向,致力于为客户提供创新特色专科领域的药物产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100003744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0033","BK0077","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2446354866","title":"海思科:考格列汀片(倍长平®)是全球首个双周口服降糖药,为全球首创,中国首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2446354866","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446354866?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:01","pubTimestamp":1719392470,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科06月26日在投资者关系平台上答复投资者关心的问题。相较于传统降糖药,倍长平具有超长疗效、肝肾无忧、平稳放心的优势,可以使临床简化治疗方案,提高了治疗的便利性和患者的依从性,从而有延缓并发症发生,节约治疗成本,提高患者生命质量的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600034620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0239","BK0028","BK0077","BK0188","BK0033"],"gpt_icon":0},{"id":"2446862982","title":"海思科:获得1类创新药考格列汀片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2446862982","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446862982?lang=zh_cn&edition=full","pubTime":"2024-06-25 14:46","pubTimestamp":1719297978,"startTime":"0","endTime":"0","summary":"中国财富通6月25日 - 海思科(002653)公告称,公司收到国家药品监督管理局下发的1类创新药考格列汀片(商品名:倍长平®,研发代号:HSK7653片)《药品注册证书》。考格列汀片是公司自主研发的,具有独立知识产权的口服治疗2型糖尿病的化学药品1类新药,为全球首个超长效DPP-4抑制剂(DPP4i)且双周口服降糖药。由于医药产品的行业特点,该药品未来生产及上市销售情况可能受到政策变化、市场需求、同类型药品市场竞争等多种不确定因素影响,具有一定不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=Mcf8lRUhGQg%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0033","06978","BK0028","BK1574","BK0239","BK0188","BK1161","002653","BK0077","159992"],"gpt_icon":0},{"id":"2446385737","title":"海思科(002653.SZ)获得1类创新药考格列汀片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446385737","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446385737?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:51","pubTimestamp":1719287503,"startTime":"0","endTime":"0","summary":"智通财经APP,海思科(002653.SZ)发布公告,公司于2024年6月25日收到国家药品监督管理局下发的1类创新药考格列汀片(商品名:倍长平®,研发代号:HSK7653片)《药品注册证书》,据称,考格列汀片是公司自主研发的,具有独立知识产权的口服治疗2型糖尿病的化学药品1类新药,为全球首个超长效DPP-4抑制剂(DPP-4i)且双周口服降糖药。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002653","BK0028","BK0077","BK0033","159992","06978","BK0239","BK0188","BK1161","BK1574"],"gpt_icon":0},{"id":"2442582201","title":"海思科最新公告:HSK42360片获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2442582201","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442582201?lang=zh_cn&edition=full","pubTime":"2024-06-12 16:41","pubTimestamp":1718181714,"startTime":"0","endTime":"0","summary":"海思科公告,公司子公司西藏海思科制药有限公司于近日收到国家药监局下发的HSK42360片《药物临床试验批准通知书》。HSK42360是公司自主研发的一种靶向BRAF V600突变且具有脑透性的小分子抑制剂,临床拟用于治疗BRAF V600突变晚期实体瘤。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200030970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK0239","BK0188","BK1576","BK0077","BK1141","BK0028","002653","BK1583","BK0033"],"gpt_icon":0},{"id":"2442058472","title":"海思科(002653.SZ):创新药HSK42360片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2442058472","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442058472?lang=zh_cn&edition=full","pubTime":"2024-06-12 16:20","pubTimestamp":1718180407,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)公告,公司子公司西藏海思科制药有限公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》,药品名称为:HSK42360片,拟用于治疗BRAF V600突变晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0239","BK0028","BK1574","03347","06978","BK0077","BK0188","159992","BK1583","002653","BK1141","BK0033","BK1161"],"gpt_icon":0},{"id":"2439637884","title":"海思科(002653)5月29日主力资金净买入834.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439637884","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439637884?lang=zh_cn&edition=full","pubTime":"2024-05-30 09:13","pubTimestamp":1717031637,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月29日收盘,海思科报收于31.35元,上涨4.12%,换手率1.13%,成交量5.85万手,成交额1.83亿元。近5日资金流向一览见下表:海思科融资融券信息显示,融资方面,当日融资买入781.74万元,融资偿还402.19万元,融资净买入379.55万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000012458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0188","BK0239","BK0077","002653","BK0028"],"gpt_icon":0},{"id":"2439455710","title":"生物医药概念盘中拉升,海思科涨6.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439455710","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439455710?lang=zh_cn&edition=full","pubTime":"2024-05-29 09:37","pubTimestamp":1716946669,"startTime":"0","endTime":"0","summary":"05月29日,生物医药概念盘中拉升,截至09点37分,生物医药概念整体指数上涨0.54%,报915.440点。从个股上来看,该概念的成分股中,海思科涨6.11%,福斯特涨幅超过5%。从资金上来看,截止发稿,生物医药概念主力净流入为-4104.61万,其中福斯特受到资金热捧,主力净流入882.22万;拉长时间线来看,该板块近20日主力资金净流入-157.20亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052909374996810591&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052909374996810591&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","002653","BK0220","BK0239","LU0211977185.USD","BK0012","BK0033","BK0054","603806","399441","LU0307460666.USD","LU0588546209.SGD","BK0070","BK0077","161726","BK0188"],"gpt_icon":0},{"id":"2438344232","title":"海思科最新公告:获得创新药HSK44459片IND申请的受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2438344232","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438344232?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:41","pubTimestamp":1716885683,"startTime":"0","endTime":"0","summary":"海思科公告,公司子公司四川海思科制药有限公司于2024年5月28日收到国家药品监督管理局下发的《受理通知书》,为HSK44459片。HSK44459片是公司自主研发的一个全新的具有独立知识产权的治疗间质性肺疾病的药物。根据国家药品监督管理局关于发布《化学药品注册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定,本品属于化学药品1类。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800029878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002653","BK0239","BK0033","BK1161","06978","BK1574","BK0077","159992","BK0188"],"gpt_icon":0},{"id":"2438434178","title":"海思科(002653.SZ)获得创新药HSK44459片IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2438434178","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438434178?lang=zh_cn&edition=full","pubTime":"2024-05-28 16:32","pubTimestamp":1716885143,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)发布公告,公司子公司四川海思科制药有限公司于2024年...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","BK0239","BK0188","BK1161","BK1574","BK0077","159992","BK0028","002653","BK0033"],"gpt_icon":0},{"id":"2437466860","title":"海思科:获得1类创新药苯磺酸克利加巴林胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437466860","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437466860?lang=zh_cn&edition=full","pubTime":"2024-05-21 13:38","pubTimestamp":1716269912,"startTime":"0","endTime":"0","summary":"中国财富通5月21日 - 海思科(002653)公告称,公司于5月21日收到国家药品监督管理局下发的1类创新药苯磺酸克利加巴林胶囊(商品名:思美宁®,研发代号:HSK16149胶囊)《药品注册证书》。除了本次获得《药品注册证书》的成人糖尿病性周围神经病理性疼痛适应症外,苯磺酸克利加巴林胶囊还于2023年9月提交了带状疱疹后神经痛适应症NDA申请,目前正在进行技术审评,有望在今年获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=zIJbjdy8e2w%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1574","BK0028","BK0188","BK0239","BK0033","BK1161","002653","BK0077","06978"],"gpt_icon":0},{"id":"2437245780","title":"海思科(002653.SZ)获得1类创新药苯磺酸克利加巴林胶囊《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2437245780","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437245780?lang=zh_cn&edition=full","pubTime":"2024-05-21 11:50","pubTimestamp":1716263455,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)发布公告,公司于2024年5月21日收到国家药品监督管...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK0028","06978","002653","BK0033","BK0239","BK0188","159992","BK0077","BK1574"],"gpt_icon":0},{"id":"2435603635","title":"海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2435603635","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435603635?lang=zh_cn&edition=full","pubTime":"2024-05-15 19:08","pubTimestamp":1715771324,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)发布公告,公司子公司西藏海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通知书》,涉及药品:“HSK39004”。公告显示,HSK39004是公司自主研发的全新的具有独立知识产权的靶向小分子抑制剂,临床拟用于气道阻力为特征的阻塞性肺病(如COPD、哮喘)的治疗。根据国家药品监督管理局关于发布《化学药品注册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定,本品属于化学药品1类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0188","BK0028","159992","06978","BK0239","BK0077","002653","BK0033","BK1161"],"gpt_icon":0},{"id":"2435563874","title":"海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435563874","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435563874?lang=zh_cn&edition=full","pubTime":"2024-05-15 18:40","pubTimestamp":1715769628,"startTime":"0","endTime":"0","summary":"海思科公告,获得创新药HSK39004吸入混悬液IND申请受理通知书。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500031597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0188","BK1161","BK0239","BK0028","06978","159992","BK0077","BK1574","002653"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":-0.0979},{"period":"3month","weight":0.1089},{"period":"6month","weight":0.2722},{"period":"1year","weight":0.363},{"period":"ytd","weight":0.3024}],"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","perCapita":"50079股","boardName":"医药制造业","registeredCapital":"111411万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":" 海思科医药集团股份有限公司的主营业务为医药研发、生产制造、销售。公司的主要产品包括创新药环泊酚注射液、甲磺酸多拉司琼注射液、多烯磷脂酰胆碱注射液、复方氨基酸注射液(18AA-Ⅶ)、氟哌噻吨美利曲辛片、注射用甲泼尼龙琥珀酸钠等。公司获得行业高度认可,连续3年荣获中国创新力医药企业,先后入选2021年度中国化药企业TOP100、2021年福布斯中国最具创新力企业TOP50榜,获评制药行业企业信用等级AAA。公司在“2022-2023年中国医药行业最具影响力榜单”评选中荣膺四项殊荣,分别是医药商业百强企业,医药制造业百强企业,自主创新先锋企业,守法诚信企业。","serverTime":1721219534743,"listedPrice":20,"stockholders":"10325人(较上一季度减少17.39%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}